Paladin acquiring Labopharm in $20M deal

Paladin Labs has struck a deal to buy Labopharm in a deal that values the biotech at a bit more than $20 million. Paladin is paying 28.5 cents a share, a significant premium over the bargain basement price of 18 cents a share Labopharm had been trading at ahead of the buyout deal. Paladin CEO Jonathan Goodman said the acquisition is "a unique opportunity for us to further strengthen our pain franchise through the addition of an established revenue stream in international markets with the potential upside provided by several product candidates." Report

Suggested Articles

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics’ CEO Aron Knickerbocker is exiting the company.

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…